Medigen Vaccine BiologicsROCO:6547 +2.09%67 Gross Margin % is 72.34% as of Dec. 2025, which is 16% above its 10-year median of 62.47. GuruFocus rates ROCO:6547 with a GF Score™ of 67/100 and a GF Value™ of NT$70.01 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Medigen Vaccine Biologics ranks worse than 51.64% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Medigen Vaccine Biologics had a gross margin of 72.34% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Medigen Vaccine Biologics Gross Margin % Related Terms
Medigen Vaccine Biologics Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6547 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Medigen Vaccine Biologics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medigen Vaccine Biologics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Medigen Vaccine Biologics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Medigen Vaccine Biologics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Medigen Vaccine Biologics (ROCO:6547) has a Gross Margin % of 72.34% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Medigen Vaccine Biologics and its competitors. This is 16% above median its historical median of 62.47. According to the industry distribution chart, Medigen Vaccine Biologics ranks #378 out of 732 companies in the Biotechnology industry, placing it in the top 51.6%.
Is Medigen Vaccine Biologics' Gross Margin % too high?
Medigen Vaccine Biologics' current Gross Margin % of 72.34% is 16% above median its 10-year median of 62.47. The Biotechnology industry median Gross Margin % is 60.91. Medigen Vaccine Biologics' value of 72.34% is 18.8% above this industry median. Based on the distribution chart, Medigen Vaccine Biologics ranks #378 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Medigen Vaccine Biologics has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Medigen Vaccine Biologics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Medigen Vaccine Biologics ranks #378 out of 732 companies for Gross Margin %. This places Medigen Vaccine Biologics in the lower half of its industry. The industry median Gross Margin % is 60.91. Medigen Vaccine Biologics' value of 72.34% is 18.8% above this benchmark. While the company's 10-year median is 62.47 vs. the industry median of 60.91, Medigen Vaccine Biologics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medigen Vaccine Biologics's current Gross Margin % of 72.34% is 18.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Medigen Vaccine Biologics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medigen Vaccine Biologics's current Gross Margin % is 72.34%, which is 16% above median its own 10-year median of 62.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medigen Vaccine Biologics stock overvalued right now?
Based on GuruFocus' analysis, Medigen Vaccine Biologics (ROCO:6547) is currently considered Possible Value Trap. The stock's GF Value™ is NT$70.01, compared to a current price of NT$46.35 — trading 33.8% below its estimated fair value. The current Gross Margin % is 72.34%, which is 16% above median its 10-year median of 62.47 and 18.8% above the Biotechnology industry median of 60.91. Medigen Vaccine Biologics' overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Medigen Vaccine Biologics (ROCO:6547), the current Gross Margin % is 72.34% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medigen Vaccine Biologics (ROCO:6547) Overvalued in 2026?
Based on GuruFocus' analysis, Medigen Vaccine Biologics stock appears to be undervalued.
The current stock price of NT$46.35 is trading 33.8% below its estimated GF Value™ of NT$70.01.
GuruFocus considers Medigen Vaccine Biologics to be Possible Value Trap.
Key valuation signals for ROCO:6547:
Gross Margin %: 72.34% (16% above median its 10-year median of 62.47)
GF Value™: NT$70.01 vs. price of NT$46.35 (33.8% below fair value)
Industry Position: 18.8% above the Biotechnology median (#378 of 732)
No single metric tells the full story. See the ROCO:6547 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medigen Vaccine Biologics Corp is engaged in the research, development and wholesale of vaccine and biopharmaceutical, medical devices wholesale and retail, etc. Its products include dengue vaccine, anti-RSV biosimilars, COVID-19 vaccines, enterovirus A71 vaccine, and influenza vaccine QIZ. It operates business only in a single industry in Taiwan.
67GF Score
Get the complete analysis for ROCO:6547
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6547 has been successfully added to your 
